Oncura is the acknowledged world leader in researching, developing and the commercialisation of Low Dose Rate (LDR) Brachytherapy. Oncura’s goal is to ensure that all cancer patients should have access to the minimally invasive benefits of brachytherapy when it is a suitable clinical option.

To achieve this we have invested heavily in delivering world class training and education to healthcare professionals. In addition to raising public awareness and access to brachytherapy for cancer treatment:

  • We will partner with our customers to increase global awareness of brachytherapy
  • We will develop brachytherapy products to treat a broad range of tumours
  • We will invest in strategic product development that aim to improve clinical outcomes

Brief history of Oncura

1991
Amersham Health™ acquires the Iodine-125 seed business from 3M™
1993
Amersham Health launches OncoSeed™
1995
Amersham Health launches RAPID Strand™, a significant advance in improving implant dosimetry and reducing seed migration
2001
Grimm et al report 87% biochemical (PSA) control at 10 years’ follow-up in 125 low risk patients with OncoSeed as monotherapy
2002
Amersham Health launches EchoSeed™
- Enhanced 3D visualisation - Suitable for the Mick™ applicator technique
2003
Amersham Seed Implant business & Galil Urology business merge to form Oncura Inc
2006
GE Healthcare acquires Oncura Seed Implant business

Key Facts on Oncura
Oncura supplies products for over 15,000 patients/year across the globe
Oncura supplies seed products to more than 400 centres worldwide
Oncura has been one of the major companies involved in LDR seed implantation for over a decade and works together with many leading centres worldwide.

USA:
Seattle Prostate Institute, Memorial Sloan Kettering Cancer Centre
Europe:
Berlin, Guildford, Leeds, Milan, Marseille, Barcelona, Madrid
photo-hospitals

Oncura Delivers world class training and service
Oncura's dedicated Business Managers and Customer Service teams provide unrivalled support across Europe, US, Canada, Latin America & Australasia.

  • Training by experienced clinicians is available worldwide (Berlin, Guidford, Leeds, Marseille, Seattle…)
  • Regular international workshops
  • All new centres undertake training with established teams
  • Networks of local user groups provide ongoing support and programme development

Oncura develops world class productsprofile-oncoseed profile-rapidstrand profile-echoseed profile-rapidstrandrx

Brachytherapy products are based on a strong scientific heritage

  • Over 2000 clinical papers published worldwide on prostate brachytherapy
  • Over 15 years work with clinicians in the development of I-125 brachytherapy programmes
  • Support major working groups including the European Collaborative Prostate Brachytherapy group, the ESTRO Probate & Braphyqs working groups

Quality throughout research and manufacturing
Oncura has a dedicated R&D and Manufacturing Facility in the USA designed to meet the highest international standards.

Your Partner of ChoiceYour partner of choice diagram